FREQUENTLY ASKED QUESTIONS
What is the official ID of this bill?
The official print number for this legislation is 118_HR_447.
Which chamber initiated this legislation?
This legislation was initiated in the House of Representatives.
When did the legislative process begin?
The process officially started on 2023-01-24.
What are the main provisions?
Key points include:
- Companies manufacturing medical products in designated economically distressed zones can receive significant tax credits, reducing their operating costs.
- Support also extends to the production of drugs and equipment critical for public health, including those protecting vulnerable populations during epidemics.
- The act seeks to strengthen the domestic supply chain for medical products, reducing reliance on foreign suppliers and enhancing citizens' health security.
What is the specific legal status?
The current status is Expired.
Where can I read the full text of this legislation?
The full official text is available at:
View full text
Who is the primary sponsor?
The primary sponsor is Rescom. González-Colón, Jenniffer [R-PR-At Large].
What is the latest detailed status?
The latest detailed status is: Introduced in House
Is this summary verified?
Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.
What is the impact of this bill?
We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.